campspot.blogg.se - Gilead copay assistance

GILEAD COPAY ASSISTANCE FULL

Missed Dose: During the maintenance period, if more than 28 weeks have elapsed since the last injection and if clinically appropriate to continue SUNLENCA treatment, restart the initiation dosage regimen from Day 1, Option 1 or Option 2.Maintenance: 927 mg by subcutaneous injection every 26 weeks +/- 2 weeks from date of last injection.Day 15: 927 mg by subcutaneous injection.

Day 8: 300 mg orally (1 x 300-mg tablet). Day 2: 600 mg orally (2 x 300-mg tablets). Initiation Option 2: Day 1: 600 mg orally (2 x 300-mg tablets).Initiation Option 1: Day 1: 927 mg by subcutaneous injection and 600 mg orally (2 x 300-mg tablets).Tablets may be taken with or without food. Dosage: Initiation with 1 of 2 options, followed by maintenance dosing once every 6 months.SUNLENCA may increase the exposure of drugs primarily metabolized by CYP3A, when initiated within 9 months after the last injection of SUNLENCA, which may increase the potential risk of adverse reactions. Drugs that strongly inhibit CYP3A, P-gp, and UGT1A1 together may significantly increase the concentration of SUNLENCA. Enzymes/transporters: Drugs that are strong or moderate inducers of CYP3A may significantly decrease the concentration of SUNLENCA.

GILEAD COPAY ASSISTANCE FULL

Prescribing information: Consult the full prescribing information for SUNLENCA for more information on Contraindications, Warnings, and potentially significant drug interactions, including clinical comments.

Most common adverse reactions (incidence ≥3%, all grades) are injection site reactions (65%) and nausea (4%).

Injection site reactions may occur, and nodules and indurations may be persistent.

If discontinuing SUNLENCA, begin alternate suppressive ARV regimen within 28 weeks from last injection. If virologic failure occurs, switch to an alternative regimen if possible. Counsel patients regarding the dosing schedule because nonadherence could lead to loss of virologic response and development of resistance. SUNLENCA may increase exposure, and potential risk of adverse reactions, to drugs primarily metabolized by CYP3A initiated within 9 months after last injection.

Long-acting properties and potential associated risks with SUNLENCA: Residual concentrations of SUNLENCA may remain in the systemic circulation of patients for up to 12 months or longer.